Caldwell Trust Co Makes New $4.63 Million Investment in Stryker Corporation $SYK

Caldwell Trust Co acquired a new stake in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 11,702 shares of the medical technology company’s stock, valued at approximately $4,630,000.

Several other institutional investors and hedge funds have also made changes to their positions in SYK. Mid American Wealth Advisory Group Inc. acquired a new position in Stryker in the 2nd quarter worth $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker in the second quarter worth about $28,000. Sachetta LLC boosted its holdings in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Kilter Group LLC purchased a new position in Stryker in the second quarter valued at about $29,000. Finally, Howard Hughes Medical Institute acquired a new stake in Stryker during the 2nd quarter valued at approximately $29,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SYK has been the subject of several research analyst reports. Evercore ISI reduced their target price on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. UBS Group set a $408.00 price objective on shares of Stryker in a research note on Monday, October 13th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a report on Monday, December 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. Finally, Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday. Twelve analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $431.83.

Insider Buying and Selling

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This represents a 2.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 522,118 shares of company stock valued at $185,381,932. Insiders own 5.20% of the company’s stock.

Stryker Stock Up 0.3%

Shares of NYSE:SYK opened at $353.99 on Monday. The company’s fifty day moving average is $366.81 and its two-hundred day moving average is $378.45. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The stock has a market capitalization of $135.37 billion, a price-to-earnings ratio of 46.52, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. Stryker’s payout ratio is currently 44.15%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.